EMA's access to documents policy would have failed to prevent cases of withheld information
This article was originally published in SRA
Executive Summary
As part of its attempts to improve transparency, the European Medicines Agency has adopted a new policy on increasing public access to documents1. However, delegates at the recent EMA/TOPRA meeting in London2 said that it would not have prevented certain instances where information had been withheld from the public.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.